Drugs / ATI-9242
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02824666 | Jun → Sep 2016 | schizophrenia | Braeburn Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATI-9242 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02824666 ↗ |
| Route | Intravenous | “administered as an IV bolus injection” NCT02824666 ↗ |